BIOMAT Database Logo BIOMAT Database Logo

B.C.N.U. (1,3-bis (2-chloroethyl) -1-nitrosourea) in the treatment of advanced Hodgkin's disease. 1972

D Cipriani, and A Strinchini

UI MeSH Term Description Entries
D009603 Nitroso Compounds Organic compounds containing the nitroso (-N Compounds, Nitroso
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol

Related Publications

D Cipriani, and A Strinchini
Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
August 1971, The New England journal of medicine,
D Cipriani, and A Strinchini
BCNU (1,3,bis(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia.
August 1968, Cancer,
D Cipriani, and A Strinchini
1,3-Bis (2-chloroethyl)-1-nitrosourea: effects on advanced ovarian carcinoma.
February 1973, American journal of obstetrics and gynecology,
D Cipriani, and A Strinchini
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
December 1971, Cancer chemotherapy reports,
D Cipriani, and A Strinchini
Genotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
June 1995, Mutation research,
D Cipriani, and A Strinchini
Antifungal action of 1,3-bis(2-chloroethyl)-1-nitrosourea.
January 1965, Antimicrobial agents and chemotherapy,
D Cipriani, and A Strinchini
Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
July 1973, American journal of obstetrics and gynecology,
D Cipriani, and A Strinchini
Reactions of 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in aqueous solution.
October 1979, Journal of medicinal chemistry,
D Cipriani, and A Strinchini
Enhanced oxygen toxicity following treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea.
October 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology,
D Cipriani, and A Strinchini
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
December 1980, Neurosurgery,
Copied contents to your clipboard!